Galectin Therapeutics Stock Today
| GALT Stock | USD 1.53 0.04 2.55% |
PerformanceGood
| Odds Of DistressQuite High
|
Galectin Therapeutics is selling for under 1.53 as of the 21st of March 2025; that is 2.55 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.53. Galectin Therapeutics has more than 66 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.76 M outstanding shares of which 7.72 M shares are currently shorted by private and institutional investors with about 31.28 trading days to cover. More on Galectin Therapeutics
Moving against Galectin Stock
Galectin Stock Highlights
| CEO President | Joel CPA |
| Thematic Idea | Israel Wall Street (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, Israel Wall Street, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Galectin Therapeutics (GALT) is traded on NASDAQ Exchange in USA. It is located in 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 and employs 14 people. Galectin Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 96.03 M. Galectin Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.76 M outstanding shares of which 7.72 M shares are currently shorted by private and institutional investors with about 31.28 trading days to cover.
Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check Galectin Therapeutics Probability Of Bankruptcy
Ownership AllocationGalectin Therapeutics has a total of 62.76 Million outstanding shares. Galectin Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Galectin Ownership Details
Galectin Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Galectin Therapeutics market risk premium is the additional return an investor will receive from holding Galectin Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1672 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | 1.53 | |||
| Sortino Ratio | 0.3383 |
Galectin Stock Against Markets
Galectin Therapeutics Corporate Management
| CPA CPA | Treasurer CFO | Profile | |
| Khurram MD | Chief Officer | Profile | |
| Jeff Katstra | Head Development | Profile | |
| Robert Tritt | General Counsel | Profile | |
| Beth Knowles | Executive Manager | Profile |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.